Quantcast

Latest Cancer immunotherapy Stories

2011-09-19 22:14:15

Regulatory protein represents potential drug target Medulloblastomas constitute the most frequent class of malignant childhood brain tumor. Tumors of this type arise due to the uncontrolled proliferation of immature nerve cells in the developing brain, and there is no targeted treatment available. A research team based at LMU℠s Center for Neuropathology and Prion Research and led by Privatdozent Dr. Ulrich Schüller has now demonstrated that the regulatory protein FoxM1...

2011-09-16 11:28:21

Some of the newest therapies in the war on cancer remove the brakes cancer puts on the immune system, Georgia Health Sciences University researchers report. These immunotherapies, such as CTLA4, strengthen the immune system's attack on cancer by keeping apart two proteins that prevent key immune cells called T cells from activating. Research featured on the cover of the Journal of Immunology suggests that these therapies also keep tumors from benefitting from IDO, an enzyme used by...

health-082311-001
2011-08-23 11:18:50

Adcetris, manufactured by Seattle Genetics, a new treatment for anaplastic large cell lymphoma and the first approved treatment for Hodgkin´s lymphoma since 1977, has been approved by the US Food and Drug Association (FDA). Seattle Genetics told Reuters on Monday that the drug will cost $4,500 dollars per vial. Patients generally received three vials per dose and between seven and nine doses per treatment, putting the price at $94,500 to $121,500 per patient, within Wall Street´s...

2011-08-18 08:00:00

WORCESTER, Mass. and TORONTO, Aug. 18, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) announced today that the Company's wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com) presented an update of the ongoing Phase 2 trial with an off-the-shelf immunotherapeutic cancer vaccine, AE37, in patients with breast cancer at Cambridge Healthtech Institute's Sixth Annual ImVacS: The Immunotherapeutics and Vaccine Summit held August 16-18,...

2011-08-10 22:55:44

Gene therapy approach provides tumor-attack roadmap for other cancers In a cancer treatment breakthrough 20 years in the making, researchers from the University of Pennsylvania's Abramson Cancer Center and Perelman School of Medicine have shown sustained remissions of up to a year among a small group of advanced chronic lymphocytic leukemia (CLL) patients treated with genetically engineered versions of their own T cells. The protocol, which involves removing patients' cells and modifying them...

2011-07-11 08:00:00

WORCESTER, Mass. and TORONTO, July 11, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today the publication of studies conducted at the Mayo Clinic using the Antigen Express proprietary Ii-Key technology. Antigen Express, Inc., the Company's wholly-owned subsidiary, has used this technology platform in the development of self-potentiating immunotherapeutic vaccines for cancer. AE37, an Ii-Key HER-2 hybrid, is currently the subject of a...

2011-06-29 03:00:00

BLUE BELL, Pa., June 29, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its therapeutic DNA vaccine for prostate cancer showed remarkable immune responses in monkeys, following similarly strong, antigen-specific and sustainable T cell levels in previously reported data from earlier animal studies. The data was presented by Dr. J. Joseph...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.